Pancreatic adenocarcinoma is a disease with a very poor prognosis and its treatment is extremely challenging. Our immunotherapeutic approach, called MBTA therapy, is based on a combination of Toll-like receptor (TLR) agonists, phagocytosis-stimulating ligand (mannan), and agonistic antibody anti-CD40. TLR agonists have a signalling effect which leads to an inflammatory response and granulocytic infiltration. Mannan is anchored to tumor cells via a biocompatible anchor for cell membrane (BAM) and labels the tumor cells for phagocytes recognition. In the case of a single tumor murine model, this mixture cured 80% of mice with pancreatic adenocarcinoma Panc02 [1] and 62.5% of mice with pheochromocytoma PHEO [2]. It was shown that early MBTA therapy initiation positively correlated with higher efficacy of MBTA therapy. In the case of large tumors or in the presence of metastases, the effect of MBTA immunotherapy is significantly reduced. For these reasons, we studied the possibility of combining our immunotherapy with the simultaneous inhibition of glutamine metabolism. Glutamine is very important for the growth and proliferation of tumor cells, and its deficiency leads to apoptosis. Combining an intratumoral application of MBTA therapy with systemic intraperitoneal application of glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) (immunometabolic therapy) resulted in a complete elimination of advanced (140.8 ± 46.8 mm3) Panc02 tumor in 50% of mice. In the case of the bilateral Panc02 model, growth reduction of both tumors and prolonged survival rate was observed. MBTA vaccination (subcutaneously applied dead Panc02 cell suspended in MBTA solution) combined with intraperitoneal application of DON improve the efficacy of treatment of distal tumors. Appropriate timing of immunometabolic therapy was also studied and the best results were obtained with intraperitoneal application of DON once a week. More frequent application was too aggressive which led to several side effects and eventually resulted in the death of mice.
TREATMENT OF ADVANCED MURINE PANCREATIC ADENOCARCINOMA BY THE COMBINATION OF MBTA IMMUNOTHERAPY WITH A GLUTAMINE ANTAGONIST
Andrea Frejlachova1, Radka Lencova1, Anna Venhauerova1, Marketa Skalickova1, Jan Zenka1
1 Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic
[1] V. Caisova, O. Uher, P. Nedbalova et al., Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis, International Immunopharmacology 59, 86-96 (2018).
[2] V. Caisova, L. Li, G. Gupta et al. The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40, Cancers 11, 654 (2019).